The shares of DOC have received an average rating of hold from around sixteen analysts who have been covering the firm. According to reports, one investment analyst has already rated the stock with a rating of sell, while seven of them have given it a rating of hold. Seven investment analysts have rated the stocks a rating buy. The target price of $19.67 over a period of a year- as explored by analysts.
The Quarterly Earnings of DOC
The stocks of DOC have received their fair share of interest from quite a few brokerage firms. Morgan Stanley has already increased the price target on the shares of the company from $14 to $16 while giving them a rating of equal weight in a research note.
ValuEnine, on the other hand, has downgraded the shares of the company from a rating of hold, to a rating of sell in one of their research reports that were published on the 17th of October. Colliers Securities has also started covering the firm, where they set a rating of buy, along with a price target of $22 on the company. The Royal Bank of Canada has also decreased the rating of the company from outperform to a rating of sector perform, with a price target of $20.
DOC traded at $0.07 last Wednesday, where they reached $17.95. The company has had a current ratio of 1.93, which is similar to the quick ratio, along with a debt-to-equity ratio of around 0.50. The market cap of the firm is $3.74 billion, with a PE ratio of around 40.86, and a PEG ratio of around 2.68, with a beta of 0.76. The year low of the firm is $11.01, with the year high fixed at $20.78. The moving average price of the firm over a period of 50-days is $17.96, while that of over 200-days is $17.86.